The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with 95% accuracy ...

Liquid biopsy detected targetable mutations in one-third of patients (n = 33) who opted for that test alone.

The researchers also followed a patient for 2.5 years and found that they could detect EML4-ALK in the liquid biopsy a good two months before it was possible to use radiography to confirm the disease.

On-Q-ity, a liquid biopsy startup based in Waltham, Mass., folded in 2013. One of its investors said the technology would likely not be market-ready for another five to 10 years.

The liquid biopsy showed her cancer had developed what’s called resistance to Tarceva, but suggested it might be knocked back by a newer drug called Tagrisso, or osimertinib. It’s another pill.

A patient at Thomas Jefferson University Hospital in Philadelphia has blood drawn for a liquid biopsy last year. The test detected a recurrence of breast cancer. (Jacqueline Larma/AP) ...